Gavin B Grant

Dr. Gavin B Grant

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 August 2006 in JAMA
Verified
Journal Article
Open access
PDF file
DCDouglas C. Chang
Douglas C. Chang
GGGavin B Grant
Gavin B Grant
KOKerry O’donnell
Kerry O’donnell
KWKathleen A. Wannemuehler
Kathleen A. Wannemuehler
JNJudith Noble-Wang
Judith Noble-Wang
FTfor the Fusarium Keratitis Investigation Team
for the Fusarium Keratitis Investigation Team
Among the estimated 34 million contact lens wearers in the United States,1 microbial keratitis (corneal infection) is a rare but serious complication that may lead to permanent vision loss or the need for corneal transplantation. The risk of microbial keratitis among contact lens wearers is about 80-fold greater than among healthy nonwearers.2 Risk factors for contact lens–associated microbial keratitis include extended wear soft lenses, overnight contact lens wear, and suboptimal adherence to recommended lens wear and care regimens.2-8 Annual incidence of microbial keratitis is estimated to be 4 to 21 per 10 000 soft contact lens wearers depending on overnight wear.9-11

1 March 2009 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
GGGavin B Grant
Gavin B Grant
HCHarry Campbell
Harry Campbell
SDScott F Dowell
Scott F Dowell
Steve GrahamSteve Graham
Steve Graham
KKKeith P Klugman
Keith P Klugman
SQShamim Qazi
Shamim Qazi

1 November 2008 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
NWNicholas D. Walter
Nicholas D. Walter
GGGavin B Grant
Gavin B Grant
UBUtpala Bandy
Utpala Bandy
NANicole E. Alexander
Nicole E. Alexander
JWJonas M. Winchell
Jonas M. Winchell
MMMatthew R. Moore
Matthew R. Moore
Background. We investigated an outbreak of severe neurologic disease and pneumonia that occurred among students at 4 schools in Rhode Island.

4 October 2019 in MMWR. Morbidity and Mortality Weekly Report
Verified
Journal Article
Closed access
GGGavin B Grant
Gavin B Grant
SDShalini Desai
Shalini Desai
LDLaure Dumolard
Laure Dumolard
KKKatrina Kretsinger
Katrina Kretsinger
SRSusan E. Reef
Susan E. Reef
Progress toward rubella elimination has resulted in 168 (87%) of 194 countries protecting infants with rubella-containing vaccine and 81 (42%) eliminating rubella transmission.

17 November 2017 in MMWR. Morbidity and Mortality Weekly Report
Verified
Journal Article
Open access
GGGavin B Grant
Gavin B Grant
SRSusan E. Reef
Susan E. Reef
MPMinal Patel
Minal Patel
JKJennifer K. Knapp
Jennifer K. Knapp
ADAlya Dabbagh
Alya Dabbagh
During 2000–2106, rubella-containing vaccine was introduced in 53 countries.

25 September 2015 in MMWR. Morbidity and Mortality Weekly Report
Verified
Journal Article
Closed access
GGGavin B Grant
Gavin B Grant
SRSusan E. Reef
Susan E. Reef
ADAlya Dabbagh
Alya Dabbagh
MGMarta Gacic-Dobo
Marta Gacic-Dobo
PSPeter M. Strebel
Peter M. Strebel
Rubella virus usually causes a mild fever and rash in children and adults. However, infection during pregnancy, especially during the first trimester, can result in miscarriage, fetal death, stillbirth, or a constellation of congenital malformations known as congenital rubella syndrome (CRS). In 2011, the World Health Organization (WHO) updated guidance on the preferred strategy for introduction of rubella-containing vaccine (RCV) into national routine immunization schedules, including an initial vaccination campaign usually targeting children aged 9 months-15 years . The Global Vaccine Action Plan endorsed by the World Health Assembly in 2012 and the Global Measles and Rubella Strategic Plan (2012-2020) published by Measles and Rubella Initiative partners in 2012 both include goals to eliminate rubella and CRS in at least two WHO regions by 2015, and at least five WHO regions by 2020 (2,3). This report updates a previous report and summarizes global progress toward rubella and CRS control and elimination during 2000-2014. As of December 2014, RCV had been introduced in 140 (72%) countries, an increase from 99 (51%) countries in 2000 (for this report, WHO member states are referred to as countries). Reported rubella cases declined 95%, from 670,894 cases in 102 countries in 2000 to 33,068 cases in 162 countries in 2014, although reporting is inconsistent. To achieve the 2020 Global Vaccine Action Plan rubella and CRS elimination goals, RCV introduction needs to continue as country criteria indicating readiness are met, and rubella and CRS surveillance need to be strengthened to ensure that progress toward elimination can be measured.